Increased risk of bleeding w/ medicinal products associated w/ bleeding risk, oral anticoagulants, ASA, heparin, SSRIs. Increased occult GI blood loss w/ naproxen. Reduced drug levels w/ CYP2C19 inhibitors eg, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, efavirenz. Decreased exposure w/ PPIs eg, omeprazole, esomeprazole. High risk of vascular events w/ boosted anti-retroviral therapy. Increased plasma conc w/ CYP2C8 substrates eg, repaglinide, paclitaxel. Caution w/ glycoprotein IIb/IIIa inhibitors, NSAIDs eg, COX-2 inhibitors.